Edward Stelmakh Optimize Rx Corp (OPRX) insider trading activity

Edward Stelmakh is Chief Finance & Strat Officer of OptimizeRx Corp. Currently has a direct ownership of 123,172 shares of OPRX, which is worth approximately $1.87 Million. The most recent transaction as insider was on Dec 23, 2025, when has been sold 3,658 shares (Common Stock) at a price of $12.74 per share, resulting in proceeds of $46,602. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 123K

0.16% 3M change

26.6% 12M change

Total Value Held $1.87 Million

Edward Stelmakh Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 23 2025	SELL Payment of exercise price or tax liability	$46,602 $12.74 p/Share	3,658 Reduced 2.88%	123,172 Common Stock
Dec 19 2025	SELL Open market or private sale	$18,751 $13.51 p/Share	1,388 Reduced 1.08%	126,830 Common Stock
Dec 19 2025	BUY Exercise of conversion of derivative security	-	5,237 Added 3.92%	128,218 Common Stock
Oct 03 2025	SELL Payment of exercise price or tax liability	$82,612 $18.75 p/Share	4,406 Reduced 3.46%	122,981 Common Stock
Oct 03 2025	BUY Exercise of conversion of derivative security	-	16,623 Added 11.54%	127,387 Common Stock
Aug 21 2025	BUY Grant, award, or other acquisition	-	15,625 Added 12.36%	110,764 Common Stock
Feb 15 2025	SELL Payment of exercise price or tax liability	$14,315 $6.64 p/Share	2,156 Reduced 2.22%	95,139 Common Stock

Dec 23 2024	BUY Grant, award, or other acquisition	-	41,408 Added 29.85%	97,295 Common Stock
Dec 19 2024	SELL Payment of exercise price or tax liability	$6,251 $4.75 p/Share	1,316 Reduced 3.41%	37,287 Common Stock
Dec 19 2024	BUY Exercise of conversion of derivative security	-	5,237 Added 11.95%	38,603 Common Stock
Oct 11 2024	SELL Payment of exercise price or tax liability	$13,697 $6.63 p/Share	2,066 Reduced 5.83%	33,366 Common Stock
Oct 11 2024	BUY Exercise of conversion of derivative security	-	8,222 Added 18.83%	35,432 Common Stock
Oct 03 2024	SELL Payment of exercise price or tax liability	$32,705 $7.83 p/Share	4,177 Reduced 13.31%	27,210 Common Stock
Oct 03 2024	BUY Exercise of conversion of derivative security	-	16,622 Added 34.62%	31,387 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	7,083 Added 32.42%	14,765 Common Stock
Oct 11 2023	SELL Payment of exercise price or tax liability	$14,771 $7.15 p/Share	2,066 Reduced 6.54%	29,537 Common Stock
Oct 11 2023	BUY Exercise of conversion of derivative security	-	6,155 Added 16.3%	31,603 Common Stock
Oct 03 2023	SELL Payment of exercise price or tax liability	$29,066 $7.06 p/Share	4,117 Reduced 19.29%	17,227 Common Stock
Oct 03 2023	BUY Exercise of conversion of derivative security	-	16,662 Added 43.84%	21,344 Common Stock
Oct 11 2022	SELL Payment of exercise price or tax liability	$99,196 $15.17 p/Share	6,539 Reduced 58.27%	4,682 Common Stock
Oct 11 2022	BUY Exercise of conversion of derivative security	-	8,221 Added 24.42%	25,448 Common Stock
Oct 11 2022	BUY Exercise of conversion of derivative security	-	8,221 Added 42.28%	11,221 Common Stock
Aug 15 2022	BUY Open market or private purchase	$46,290 $15.43 p/Share	3,000 Added 50.0%	3,000 Common Stock

Edward Stelmakh

Chief Finance & Strat Officer

Rochester, MI

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells OPRX shares.

Notify only if

Value

Insider Trading

Get notified when an Optimize Rx Corp insider buys or sells OPRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to OptimizeRx Corp

Track Activities on OPRX

Account